Vitrasert for cytomegalovirus (CMV) retinitis
April 1996
The FDA just approved Vitrasert for cytomegalovirus (CMV) retinitis. Vitrasert is implanted surgically in the eye. It releases the antiviral ganciclovir for about six months.
The implant works better than IV ganciclovir...probably because it achieves higher drug levels in the eye.
Vitrasert DOESN'T prevent CMV infections in the other eye or elsewhere in the body. Expect to see some patients get combo therapy with Vitrasert AND systemic ganciclovir (Cytovene).
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote